Survodutide: Common Questions and What the Literature Says

Survodutide (development code BI 456906) is an investigational once-weekly dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Searches such as survodutide peptide benefits often return promotional language rather than trial reports. This page summarises only what the verified published literature described, names the trial that produced each finding, and states plainly where no published study exists.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. Nothing here is a protocol, a recommendation, or a description of what any individual should do.

What Survodutide Is, According to the Preclinical Literature

Survodutide was characterised in the preclinical literature as a novel GCGR/GLP-1R dual agonist. The discovery and pharmacology report described robust anti-obesity efficacy in preclinical models, distinguishing the molecule from single-receptor GLP-1 agonists by the addition of glucagon receptor activity (PMID 36356832). A companion pharmacological profiling paper described the biomarkers and profiling work that researchers used to support clinical candidate selection for the dual GCGR/GLP-1R agonist programme (PMID 38560764).

Narrative reviews later framed the compound within cardiometabolic drug development, describing the dual GLP-1/glucagon mechanism and the investigational status of the agent at the time of writing (PMID 40963161), and discussed the rationale for targeting both hepatic and systemic metabolic dysfunction in metabolic dysfunction-associated steatohepatitis (MASH) (PMID 39663847).

Obesity: What the Phase 2 Dose-Finding Trial Reported

The phase 2 programme in obesity was published as a randomised, double-blind, placebo-controlled, dose-finding trial. The study evaluated subcutaneous survodutide at doses up to 4.8 mg once weekly in adults with obesity and reported dose-dependent reductions in body weight compared with placebo, with the larger reductions seen in the higher-dose groups (PMID 38330987). Researchers described the trial as dose-finding, meaning its purpose was to characterise the dose-response relationship and tolerability rather than to establish long-term outcomes (PMID 38330987).

Obesity: What the Phase 3 Literature Has Published

A phase 3 report of once-weekly survodutide in adults with obesity was published in The New England Journal of Medicine, presenting randomised trial results for the treatment of adults with obesity (PMID 42253238). Separately, a baseline characteristics paper described the population enrolled in SYNCHRONIZE-1, a randomised, double-blind, placebo-controlled phase 3 trial of survodutide for the treatment of obesity, documenting who entered the trial before efficacy analyses were reported (PMID 41187967).

Baseline-characteristics publications of this kind do not report efficacy or adverse-event outcomes; they exist so that readers of the later results paper can judge generalisability (PMID 41187967).

Type 2 Diabetes: What the Dose-Response Trial Reported

In people with type 2 diabetes, a randomised clinical trial examined dose-response effects of survodutide on HbA_1c and body weight. The study compared survodutide doses up to 3.6 mg once weekly with placebo and with open-label semaglutide, and researchers reported reductions in HbA_1c and body weight relative to placebo across the dose range studied (PMID 38095657). Because the semaglutide arm was open-label rather than blinded, the authors framed it as a reference comparator rather than a formal head-to-head superiority test (PMID 38095657).

Liver Disease: MASH, MASLD and Cirrhosis

Phase 2 MASH trial

A phase 2 randomised trial in adults with MASH and fibrosis evaluated survodutide at doses of 2.4 mg, 4.8 mg and 6.0 mg once weekly. The study's primary endpoint was histological improvement in MASH with no worsening of fibrosis, and a higher proportion of participants assigned to survodutide than to placebo met that endpoint (PMID 38847460). Researchers reported the trial as a phase 2 evaluation, so the findings were described as supporting further study rather than as definitive outcome data (PMID 38847460).

Phase 3 MASLD trial

SYNCHRONIZE-MASLD was published as a randomised, double-blind, placebo-controlled phase 3 trial of survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) (PMID 42252333). This trial extended the liver-focused programme from phase 2 histology endpoints into a larger phase 3 population defined by obesity plus MASLD (PMID 42252333).

Cirrhosis

A separate study in the Journal of Hepatology examined the efficacy, tolerability and pharmacokinetics of survodutide in cirrhosis, a population in which drug handling can differ from that in people with preserved liver function (PMID 38857788). Pharmacokinetic studies of this type are designed to characterise exposure and tolerability in a specific hepatic-impairment population rather than to demonstrate clinical benefit (PMID 38857788).

Cardiovascular Outcomes: What Has Been Described So Far

A design and rationale paper described the SYNCHRONIZE cardiovascular outcomes trial of survodutide for the treatment of obesity, setting out the planned population, comparator and endpoint framework (PMID 39453356). Design papers report no efficacy findings. In the verified literature summarised here, no completed cardiovascular outcome results for survodutide were reported; only the trial rationale and design were published (PMID 39453356).

Tolerability and Adverse Events: What Studies Report

Across the published trials, gastrointestinal adverse events were the most frequently reported category. In the phase 2 obesity dose-finding trial, researchers reported that gastrointestinal events such as nausea and vomiting occurred more often with survodutide than with placebo and were linked to the dose-escalation phase of the study (PMID 38330987). The phase 2 MASH trial similarly reported gastrointestinal adverse events as the most common events among participants receiving survodutide at 2.4 mg to 6.0 mg once weekly (PMID 38847460).

The type 2 diabetes dose-response trial also reported gastrointestinal tolerability as a key consideration in interpreting the dose-response relationship for survodutide doses up to 3.6 mg weekly (PMID 38095657). In cirrhosis, tolerability was one of the co-primary considerations alongside pharmacokinetics (PMID 38857788). Adverse-event frequencies, discontinuation rates and severity gradings differ between trials and are reported in full only in each original publication.

Published Trials at a Glance

Questions the Literature Does Not Answer

Several common search questions have no answer in the published trial literature summarised here:

• Use in healthy adults for body composition or appearance. The verified trials enrolled adults with obesity, type 2 diabetes, MASH, MASLD or cirrhosis (PMID 38330987, PMID 38847460). No published study in the verified set examined healthy-weight adults.
• Head-to-head phase 3 comparisons with other incretin agents. The only comparator arm described was open-label semaglutide within a phase 2 dose-response trial in type 2 diabetes (PMID 38095657).
• Long-term cardiovascular event outcomes. Only the trial design was published (PMID 39453356).
• Unregulated, "research-use-only" or compounded material. No study in the verified list evaluated non-pharmaceutical survodutide products, so trial findings cannot be extended to them.
• Effects after stopping treatment, in pregnancy, or in adolescents. These populations and questions were not covered by the verified publications.

How to Read "Benefits" Claims About Survodutide

The published record for survodutide consists of preclinical pharmacology, phase 2 dose-finding trials in obesity, type 2 diabetes and MASH, phase 2 pharmacokinetic work in cirrhosis, phase 3 trials in obesity and MASLD, and a cardiovascular outcomes trial design. Reviews describing the agent placed it within a class of dual GLP-1/glucagon receptor agonists under investigation for cardiometabolic disease (PMID 40963161, PMID 39663847). Effects reported in these trials were measured in defined patient populations, at defined doses, over defined durations, and under trial-specified dose escalation and monitoring. Nothing in this summary describes a regimen, and nothing here should be read as guidance about use.

References

• BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy (Molecular Metabolism, 2022)
• Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial (Diabetologia, 2024)
• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (The Lancet Diabetes & Endocrinology, 2024)
• The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection (Diabetes, Obesity & Metabolism, 2024)
• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (The New England Journal of Medicine, 2024)
• Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis (Journal of Hepatology, 2024)
• Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial (JACC: Heart Failure, 2024)
• Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction (Expert Opinion on Investigational Drugs, 2024)
• Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care (Cardiology in Review, 2025)
• Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1) (Diabetes, Obesity & Metabolism, 2026)
• Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (Nature Medicine, 2026)
• Survodutide Once Weekly for the Treatment of Adults with Obesity (The New England Journal of Medicine, 2026)